The players involved in the Pharmaceutical industry, a capital-intensive one, strive hard to maintain average margin ratios such as the net profit margin, atleast matching those of others present in the segment.
Listed below are three stocks that have a Net Profit Margin of more than xx percent during FY2022-2023:
Caplin Point Laboratories Limited
With a market capitalization of Rs 8,393.72 crores, the stocks of Caplin Point Laboratories Limited, associated with the manufacturing of pharmaceutical products including capsules, dry powder, soft gels, etc, are currently trading at Rs 1,105.40, slipping around 0.80 percent as compared to the previous closing levels of Rs 1,113.95 apiece.
In recent years, the company has been successful in increasing its operating revenues as well as after-tax profits with the former moving up from Rs 1,269 crores during FY21-22 to Rs 1,466 crores during FY22-23, and, the latter, during the same timeframe, taking a shift from Rs 308 crores to Rs 376 crores.
In addition to the above, the company reported a net profit margin of 25.69 percent during FY2022-2023.
Suven Pharmaceuticals Limited
With a market capitalization of Rs 13,035 crores, the stocks of Suven Pharmaceuticals Limited, engaged in the business of developing as well as manufacturing specialty chemicals, etc, are currently trading at Rs 512.05, gaining around 0.95 percent as compared to the previous closing levels of Rs 507.35 apiece.
In addition to the above, the company reported a net profit margin of 30.68 percent during FY2022-2023.
Alembic Limited
With a market capitalization of Rs 2,136.42 crores, the stocks of Alembic Limited, engaged in the business of manufacturing Active Pharmaceutical Ingredients (APIs), are currently trading at Rs 83.20, slipping around 1.80 percent as compared to the previous closing levels of Rs 84.66 apiece.
In recent years, the company has been successful in increasing its operating revenues from Rs crores during FY21-22 to Rs crores during FY22-23. On the contrary, the after-tax profits of the company took a marginal downshift from Rs 86 crores to Rs 80 crores.
In addition to the above, the company reported a net profit margin of 63.35 percent during FY2022-2023.
Written by Amit Madnani
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
